Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Effect of Reactive Functional Motor Challenge Training on Dynamic Balance and Functional Mobility in Children With Spastic Diplegic Cerebral Palsy: A Randomized Comparative Trial.

NCT07732881 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-13
Last updated
2026-07-29

Condition(s) studied

Cerebral Palsy (CP)Spastic Diplegia Cerebral Palsy

Investigational drug(s) / intervention(s)

Reactive Functional Motor Challenge TrainingConventional Physical Therapy Program

Reactive Functional Motor Challenge Training: The experimental group will receive Reactive Functional Motor Challenge Training using . Foam balance pads * Therapy steps * Cones * Obstacles * Elastic resistance bands * Therapy balls * Floor markers * Colored targets * Balance discs * Mats * Rollator * Wege * Balance beam

Conventional Physical Therapy Program: while the control group will receive conventional physical therapy. Outcome measures will be assessed before and after the intervention

Study summary

To investigate the effect of Reactive Functional Motor Challenge Training on dynamic balance and functional mobility in children with spastic diplegic cerebral palsy.

Eligibility

Sex
ALL
Min age
8 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with spastic diplegic cerebral palsy. * Grade 1and 1+ according to the Modified Ashworth scale. * They can walk alone, with limitation, GMFCS Levels I-II. * Able to follow simple verbal instructions. Exclusion Criteria: * Orthopedic surgery during the previous 12 months. * Botulinum toxin injection within the previous 6 months. * Severe cognitive impairment preventing cooperation. * Uncontrolled epilepsy. * Fixed musculoskeletal deformities limiting functional activities. * Children who suffer from other diseases or associated disorders that interfere with physical activity.

Primary outcome measure(s)

  • Paediatric Balance Scale (PBS) — 3 Months
  • Four Square Step Test (FSST) — 3 Months

Trial sites (1)

FacilityCityRegionStatus
Private clinics Cairo Cairo Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07732881 on ClinicalTrials.gov ↗ ← All trials in Egypt